DB:2VN

Stock Analysis Report

Biohaven Pharmaceutical Holding

Executive Summary

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Biohaven Pharmaceutical Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2VN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.5%

2VN

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

9.8%

2VN

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 2VN matched the German Biotechs industry which returned 10% over the past year.

Return vs Market: 2VN underperformed the German Market which returned 12.8% over the past year.


Shareholder returns

2VNIndustryMarket
7 Day-0.5%0.4%-0.9%
30 Day-16.8%-3.2%-0.4%
90 Day-18.4%4.6%2.3%
1 Year9.8%9.8%10.3%10.0%16.3%12.8%
3 Yearn/a49.4%47.8%15.8%5.7%
5 Yearn/a13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Biohaven Pharmaceutical Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biohaven Pharmaceutical Holding undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2VN (€42) is trading below our estimate of fair value (€302.24)

Significantly Below Fair Value: 2VN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2VN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2VN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2VN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2VN is overvalued based on its PB Ratio (19.9x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Biohaven Pharmaceutical Holding forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

55.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2VN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2VN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2VN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2VN's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 2VN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2VN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biohaven Pharmaceutical Holding performed over the past 5 years?

-52.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2VN is currently unprofitable.

Growing Profit Margin: 2VN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2VN is unprofitable, and losses have increased over the past 5 years at a rate of -52% per year.

Accelerating Growth: Unable to compare 2VN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2VN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 2VN has a negative Return on Equity (-365.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Biohaven Pharmaceutical Holding's financial position?


Financial Position Analysis

Short Term Liabilities: 2VN's short term assets ($423.2M) exceed its short term liabilities ($47.2M).

Long Term Liabilities: 2VN's short term assets ($423.2M) exceed its long term liabilities ($272.9M).


Debt to Equity History and Analysis

Debt Level: 2VN's debt to equity ratio (83.4%) is considered high.

Reducing Debt: Insufficient data to determine if 2VN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 2VN has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2VN's debt is covered by short term assets (assets are 4.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2VN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2VN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -57.6% each year.


Next Steps

Dividend

What is Biohaven Pharmaceutical Holding's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2VN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2VN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2VN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2VN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2VN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Vlad Coric (48yo)

4.3yrs

Tenure

US$7,854,000

Compensation

Dr. Vladimir Coric, also known as Vlad, M.D., has been the Chief Executive Officer at Biohaven Pharmaceutical Holding Company Ltd. since October 2015. Dr. Coric has over 14 years of clinical trial experien ...


CEO Compensation Analysis

Compensation vs Market: Vlad's total compensation ($USD7.85M) is above average for companies of similar size in the German market ($USD2.28M).

Compensation vs Earnings: Vlad's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Vladimir Coric
CEO & Director4.3yrsUS$7.85m1.65% $39.2m
James Engelhart
Chief Financial Officer & Treasurer3.8yrsUS$3.22m0.0079% $188.7k
Charles Conway
Chief Scientific Officer3.1yrsUS$2.79m0.0099% $235.4k
John Tilton
Chief Commercial Officer of Rare and Orphan Diseases3.8yrsUS$1.53m0.0014% $32.2k
Kimberly Gentile
Senior Vice President of Clinical Operations1.1yrsUS$2.78m0.0064% $152.0k
Clifford Bechtold
Chief Operating Officer2.3yrsno datano data
Matthew DeLawder
Director of Accounting1.2yrsno datano data
Wendy Goss
Executive Administrative Assistant0yrsno datano data
Robert Berman
Chief Medical Officer4.3yrsUS$521.06k1.39% $33.0m
Elyse Stock
Chief Medical Officer2.7yrsno data0.0049% $116.0k

3.1yrs

Average Tenure

54yo

Average Age

Experienced Management: 2VN's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vladimir Coric
CEO & Director4.3yrsUS$7.85m1.65% $39.2m
John Childs
Independent Director6.1yrsUS$660.14k4.97% $118.4m
Julia Gregory
Independent Director2.5yrsUS$682.19kno data
Gregory Bailey
Independent Director6.1yrsUS$660.14k4.53% $108.0m
Michael Heffernan
Independent Director0.08yrsno datano data
Declan Doogan
Chairman of the Board0yrsUS$706.36k2.28% $54.3m
Maurizio Fava
Member of Scientific Advisory Board0yrsno datano data
Richard Lipton
Chairman of Scientific Advisory Board0yrsno datano data
John Krystal
Member of Scientific Advisory Board0yrsno datano data
Gerard Sanacora
Member of Scientific Advisory Board0yrsno datano data

4.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 2VN's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.1%.


Top Shareholders

Company Information

Biohaven Pharmaceutical Holding Company Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biohaven Pharmaceutical Holding Company Ltd.
  • Ticker: 2VN
  • Exchange: DB
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.588b
  • Listing Market Cap: US$2.382b
  • Shares outstanding: 57.07m
  • Website: https://www.biohavenpharma.com

Number of Employees


Location

  • Biohaven Pharmaceutical Holding Company Ltd.
  • 215 Church Street
  • New Haven
  • Connecticut
  • 6510
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BHVNNYSE (New York Stock Exchange)YesCommon SharesUSUSDMay 2017
2VNDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2017

Biography

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 22:41
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.